Penicillin allergies can increase the risk of drug resistant 'superbug' infections, according to a study.
The risk is largely due to the use of more 'broad spectrum' antibiotics as alternatives to penicillin, which may be fuelling the development of drug resistant bacteria.
The researchers argue that addressing penicillin allergies "may be an important public health strategy to reduce the incidence of MRSA and C difficile among patients with a penicillin allergy label."
Penicillin allergy is the most commonly documented drug allergy, reported by about 10 percent of patients. However, previous studies have shown that more than 90 percent of patients with listed penicillin allergies can be safely treated with penicillins.
To evaluate the public health consequences of a penicillin allergy label, researchers at Massachusetts General Hospital in Boston examined the relation between penicillin allergy and development of MRSA and C difficile.
After adjusting for several known risk factors, the researchers found that a penicillin allergy label was associated with a 69 percent increased risk of MRSA and a 26 percent increased risk of C difficile.
Once documented, a penicillin allergy was associated with increased use of alternative 'broad spectrum' antibiotics, which act against a wider range of bacteria.
The results show that increased use of broad spectrum antibiotics accounted for more than half (55 percent) of the increased MRSA risk and more than one third (35 percent) of the increased C difficile risk among patients with a listed penicillin allergy.
This is an observational study, so no firm conclusions can be drawn about cause and effect, and the researchers cannot rule out the possibility that other, unmeasured factors may have affected their results. However, they point out that this was a large, representative sample and the findings remained consistent after further analyses to test the strength of the results.
As such, they conclude that patients with a documented penicillin allergy "have an increased risk of new MRSA and C difficile that may be modifiable, to some degree, through changes in antibiotic prescribing."
As infections with resistant organisms increase, "systematic efforts to confirm or rule out the presence of true penicillin allergy may be an important public health strategy to reduce the incidence of MRSA and C. difficile," they added.
The study has been published in The BMJ.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
